Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial - The Lancet

Por um escritor misterioso
Last updated 21 setembro 2024
Factor XIa inhibition with asundexian after acute non-cardioembolic  ischaemic stroke (PACIFIC-Stroke): an international, randomised,  double-blind, placebo-controlled, phase 2b trial - The Lancet
Factor XIa inhibition with asundexian after acute non-cardioembolic  ischaemic stroke (PACIFIC-Stroke): an international, randomised,  double-blind, placebo-controlled, phase 2b trial - The Lancet
Factor XIa inhibition with asundexian after acute non
Factor XIa inhibition with asundexian after acute non-cardioembolic  ischaemic stroke (PACIFIC-Stroke): an international, randomised,  double-blind, placebo-controlled, phase 2b trial - The Lancet
PDF) The new era of anticoagulation: factor XI and XII inhibitors
Factor XIa inhibition with asundexian after acute non-cardioembolic  ischaemic stroke (PACIFIC-Stroke): an international, randomised,  double-blind, placebo-controlled, phase 2b trial - The Lancet
Factor XIa inhibition with asundexian after acute non
Factor XIa inhibition with asundexian after acute non-cardioembolic  ischaemic stroke (PACIFIC-Stroke): an international, randomised,  double-blind, placebo-controlled, phase 2b trial - The Lancet
Pharmaceuticals, Free Full-Text
Factor XIa inhibition with asundexian after acute non-cardioembolic  ischaemic stroke (PACIFIC-Stroke): an international, randomised,  double-blind, placebo-controlled, phase 2b trial - The Lancet
Clinical Evaluation of Factor XIa Inhibitor Drugs: JACC Review
Factor XIa inhibition with asundexian after acute non-cardioembolic  ischaemic stroke (PACIFIC-Stroke): an international, randomised,  double-blind, placebo-controlled, phase 2b trial - The Lancet
Safety and efficacy of factor XIa inhibition with milvexian for
Factor XIa inhibition with asundexian after acute non-cardioembolic  ischaemic stroke (PACIFIC-Stroke): an international, randomised,  double-blind, placebo-controlled, phase 2b trial - The Lancet
Asundexian (BAY-2433334), CAS 2064121-65-7
Factor XIa inhibition with asundexian after acute non-cardioembolic  ischaemic stroke (PACIFIC-Stroke): an international, randomised,  double-blind, placebo-controlled, phase 2b trial - The Lancet
Ischaemic stroke despite antiplatelet therapy: Causes and outcomes
Factor XIa inhibition with asundexian after acute non-cardioembolic  ischaemic stroke (PACIFIC-Stroke): an international, randomised,  double-blind, placebo-controlled, phase 2b trial - The Lancet
Ischaemic stroke despite antiplatelet therapy: Causes and outcomes

© 2014-2024 immanuelipc.com. All rights reserved.